Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and fluid for hydration, preventing ketosis by providing a minimal carbohydrate source. Sodium chloride 0.9% supplies electrolytes and maintains osmotic pressure in extracellular fluid.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement in patients with isotonic dehydration,Maintenance of hydration and electrolyte balance when oral intake is inadequate,Vehicle for intravenous administration of compatible drugs,Hypovolemia (off-label),Shock (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; typical adult dose is 500-1000 m L as a single dose, administered at a rate determined by clinical condition (e.g., 100-200 m L/h for maintenance).
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Glucose has a plasma half-life of approximately 1.5-2.5 hours in normal individuals, reflecting rapid cellular uptake and metabolism. Sodium and chloride have no definable half-life as they are actively regulated; however, the half-life of infused sodium is approximately 2-4 hours depending on renal function.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the Krebs cycle to carbon dioxide and water; insulin-dependent. Sodium chloride is not metabolized; excreted renally.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Glucose is completely metabolized to CO2 and water; renal excretion of unchanged glucose is negligible (<1%) in normoglycemic patients. Sodium and chloride are primarily excreted renally (90-95% of infused load) with small fecal and sweat losses. In dextrose 5% and sodium chloride 0.9%, both components are eliminated renally; the dextrose is metabolized, not excreted unchanged.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: negligible (<1%) binding to plasma proteins. Sodium: not protein-bound. Chloride: not protein-bound.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: Vd approximately 0.15-0.25 L/kg (primarily extracellular fluid). Sodium and chloride: Vd approximately 0.25 L/kg (distributes into extracellular space). Total body water distribution occurs only if free water is present.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% bioavailability. Not administered orally for these purposes; if ingested, dextrose undergoes first-pass metabolism (oral bioavailability ~50-60% due to hepatic extraction) and sodium chloride is fully absorbed.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Not applicable; contains sodium chloride and dextrose; monitor serum sodium and glucose in renal impairment. For GFR <30 m L/min, use with caution due to risk of hypernatremia and fluid overload.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustment; monitor blood glucose in hepatic impairment due to risk of hyperglycemia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion; dose based on fluid and electrolyte needs, typically 5-10 m L/kg per hour, adjusted for clinical response; maximum rate 20 m L/kg/h in neonates.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution; lower infusion rates recommended due to reduced renal function and higher risk of fluid overload and electrolyte disturbances; monitor serum sodium and glucose closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No FDA black box warnings.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Hyperglycemia in patients with diabetes or stress-induced hyperglycemia,Fluid overload in patients with heart failure, renal impairment, or edematous states,Hyponatremia (especially in children, elderly, and post-operative patients),Hypernatremia with excessive administration,Osmotic demyelination syndrome with rapid correction of hyponatremia,Phlebitis or extravasation at infusion site
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia (severe) when dextrose use is inadvisable,Hypernatremia,Acute intracranial hemorrhage (if using hypotonic solutions, but not applicable here),Severe renal impairment (oliguria/anuria) with volume overload risk,Patients with known hypersensitivity to dextrose or corn-based products
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No direct food interactions. However, monitor total sodium and glucose intake if patient is on a restricted diet for diabetes or hypertension.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk at standard doses. Excessive sodium may cause maternal hypernatremia with fetal effects indirectly. No trimester-specific risks.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Exogenous dextrose and sodium chloride are normal blood constituents; negligible transfer into milk. M/P ratio not applicable. Compatible with breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No specific dose adjustments for dextrose 5% and sodium chloride 0.9%; use standard dosing. Monitor for gestational hyperglycemia and edema; adjust rate based on clinical status.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Must confirm IV access patency before infusion; hypertonic 0.9% Na Cl may cause phlebitis. Use with caution in heart failure, renal impairment, or hypernatremia. Monitor serum glucose and sodium levels during prolonged administration. Not suitable for dilution of incompatible medications.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Inform your doctor if you have heart disease, kidney problems, or high blood pressure.,Report any signs of allergic reaction (rash, itching, swelling) or infusion site pain/redness.,This solution provides sugar and salt; your fluid and electrolyte levels will be monitored.,Do not stop or adjust the infusion rate without medical advice.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is a Electrolyte that works by Dextrose 5% provides a source of calories and fluid for hydration, preventing ketosis by providing a minimal carbohydrate source. Sodium chloride 0.9% supplies electrolytes and maintains osmotic pressure in extracellular fluid.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is: Intravenous infusion; typical adult dose is 500-1000 m L as a single dose, administered at a rate determined by clinical condition (e.g., 100-200 m L/h for maintenance).. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk at standard doses. Excessive sodium may cause maternal hypernatremia with fetal effects indirectly. No . AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.